1. C4 Therapeutics Secures New Roche Deal for Degrader-Antibody Conjugate Platform
C4 Therapeutics has inked a new strategic collaboration and license agreement with pharmaceutical giant Roche, focusing on the development of degrader-antibody conjugates (DACs). This deal signals continued validation for C4T's targeted protein degradation platform and deepens its existing partnership with one of the w...